Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O7PT
|
|||
| Former ID |
DNC000322
|
|||
| Drug Name |
Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]
|
|||
| Synonyms |
Loxiglumide; LOXIGLUMIDE; 107097-80-3; Loxiglumide [INN]; Loxiglumidum [Latin]; Loxiglumida [Spanish]; CR 1505; CR-1505; CHEMBL206025; (+-)-4-(3,4-Dichlorobenzamido)-N-(3-methoxypropyl)-N-pentylglutaramic acid; 4-(3,4-dichlorobenzamido)-5-((3-methoxypropyl)(pentyl)amino)-5-oxopentanoic acid; (+-)-4-((3,4-Dichlorobenzoyl)amino)-5-((3-methoxypropyl)pentylamino)-5-oxopentanoic acid; D,L-4-(3,4-Dichlorobenzoylamino)-5-(N-3-methoxypropylpentylamino)-5-oxo-pentanoic acid; Loxiglumidum; Loxiglumida; Pentanoic
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1], [2], [3] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H30Cl2N2O5
|
|||
| Canonical SMILES |
CCCCCN(CCCOC)C(=O)C(CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl
|
|||
| InChI |
1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)
|
|||
| InChIKey |
QNQZBKQEIFTHFZ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 107097-80-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7848176, 8186711, 12014112, 14858173, 43117613, 50002824, 50595051, 57313995, 85209678, 103483749, 104069481, 104320084, 117462170, 125823047, 126666685, 129049181, 134339776, 134340190, 135016969, 135650534, 137246280, 137267638, 152343551, 162011536, 170465971, 174526056, 175612456, 179149551, 184546007, 223654106, 226715875, 242060146, 249582653, 252351363
|
|||
| ChEBI ID |
CHEBI:31785
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cholecystokinin receptor (CCKR) | Target Info | Antagonist | [4] |
| Cholecystokinin receptor type A (CCKAR) | Target Info | Antagonist | [5] | |
| Neuropeptide Y receptor type 5 (NPY5R) | Target Info | Agonist | [3] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Calcium signaling pathway | ||||
| Insulin secretion | ||||
| Pancreatic secretion | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 892). | |||
| REF 2 | Effects of CCK receptor blockade on intestinal motor activity in conscious dogs. Am J Physiol. 1991 Feb;260(2 Pt 1):G315-24. | |||
| REF 3 | Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]: a neuropeptide Y (NPY) Y(5) receptor selective agonist with a latent stimulatory effect on food intake in rats. Peptides. 2002 Aug;23(8):1485-90. | |||
| REF 4 | Cholecystokinin receptor antagonist, loxiglumide, inhibits invasiveness of human pancreatic cancer cell lines. FEBS Lett. 1996 Apr 1;383(3):241-4. | |||
| REF 5 | Role of CCK(A) receptors in postprandial lower esophageal sphincter function in morbidly obese subjects. Dig Dis Sci. 2002 Nov;47(11):2531-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.